FDA advisers back updating COVID vaccines for XFG variant in 2026-27
FDA advisers backed an XFG-based COVID vaccine update for 2026-27 as surveillance weakened and officials weighed who still needs the next shot most.
Americans heading into the next COVID vaccine season are likely to see shots tuned to XFG, the strain now dominating circulation, a move that could keep protection against severe illness on track even as the virus keeps shifting. The FDA’s vaccine advisers voted 8-1 to recommend an update for the 2026-2027 campaign, backing a formula meant to match the variant most widely in circulation.
The recommendation came despite unease inside the agency about how thin the data have become. Anna Durbin of Johns Hopkins said recommendations are harder when the evidence is sparse and argued that real-time surveillance needs to improve, adding that the panel may need to meet more than once a year. Her warning landed against a backdrop of weakened national tracking, with CDC sequencing data limited by low submissions and the agency’s most recent national update already a month old.
The World Health Organization had already pointed vaccine makers toward current strains. On May 16, 2026, WHO said monovalent LP.8.1 remained the recommended antigen, but XFG and NB.1.8.1 were also acceptable if they produced broad, robust immune responses. WHO described XFG as a recombinant of LF.7 and LP.8.1.2, with the earliest sample collected on January 27, 2025, and it classified the variant under monitoring on June 25, 2025.
That scientific judgment matters because the next season’s shots are still expected to look familiar to U.S. consumers. Four COVID vaccines are approved in the United States, and manufacturers say they can produce updated doses in time for the coming season. The FDA’s vaccine committee is scheduled to meet in open session on May 28, 2026, to discuss the 2026-2027 formula, a year after it met on May 22, 2025, to recommend the 2025-2026 version.
The policy fight around vaccines, however, extends well beyond strain selection. Under Health Secretary Robert F. Kennedy Jr., COVID and other vaccine policy has drawn scrutiny and changes, even as this advisory panel remained in place. CDC said on January 5, 2026, that Acting Director Jim O’Neill signed a memorandum accepting recommendations tied to childhood immunization practices, and CDC and HHS later announced two new physicians to ACIP in a March release. CDC says ACIP recommendations become official agency policy once adopted by the CDC Director, making the stakes of each vote far larger than a technical update.
This article was produced by Prism’s automated news system from verified source data, official records, and press releases, then run through automated quality and moderation checks before publishing. The system is built and supervised by the people who set the standards it runs under. Read our full AI policy.
Know something we missed? Have a correction or additional information?
Submit a Tip
